Business

Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer

Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq:

articleContext Therapeutics Inc.November 1, 20214/company/context-therapeutics-inc/news/context-therapeuticsr-strengthens-leadership-team-with-appointments-of-chief-financial-officer-and-chief-legal-officer
Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer

About this update from Context Therapeutics Inc.

[{"type":"text","content":"Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO\nPHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the appointment of Jennifer Minai-Azary as Chief Financial Officer and the prior appointment, in April 2021, of Alex Levit as Chief Legal Officer. “It is an exciting time for the company following our recent debut on Nasdaq and I’d like to thank Alex for all of his contributions to help make this happen. I’m also pleased to welcome Jennifer Minai-Azary to Context’s leadership team,” said Martin Lehr, Chief Executive Officer of Context. “Jennifer’s and Alex’s deep biopharma financial and legal expertise, respectively, and their proven leadership skills will be instrumental to Context as we navigate this new chapter for the company and work to deliver on our near- and long-term corporate and clinical milestones.” Ms. Minai-Azary brings more than 20 years of finance and accounting experience to Context. Prior to joining Context, Ms. Minai-Azary served in roles of increasing responsibility at Millendo Therapeutics, culminating in chief financial officer, where she led financial operations, including guiding the company’s merger with Tempest Therapeutics, a clinical-stage oncology company. Earlier in her career, Ms. Minai-Azary was director of technical accounting at Parexel and began her career in Ernst & Young’s audit practice. Ms. Minai-Azary holds a Master of Accounting and a Bachelor of Business Administration from the University of Michigan and is a certified public accountant. “I’m excited to join Context at this important juncture in the company’s growth and I look forward to leading the company’s finance organization,” said Ms. Minai-Azary. “I am eager to help deliver on the company’s ongoing commitment to provide patients with more therapeutic options and to drive long-term value for our shareholders.” Mr. Levit is a seasoned legal advisor with nearly two decades of industry experience advising public and private companies. Prior to joining Context, Mr. Levit served as vice president, deputy general counsel and assistant corporate secretary of OptiNose, a publicly held specialty pharmace...

More updates from Context Therapeutics Inc.